Klaria Pharma
Klaria Year-End Report 2024
Summary of the report
Fourth quarter of 2024
The group in total
- Net sales 1.1 MSEK (1.3 MSEK)
- Other income 0.0 MSEK (0.3 MSEK)
- R&D expenses for the quarter amounted to 9.3 MSEK (1.9 MSEK)
- Profit after tax amounted to -15.6 MSEK (-9.5 MSEK)
- Earnings per share for the quarter amounted to -0.11 SEK (-0.09 SEK)
- Cash flow from operating activities amounted to 1.0 MSEK (9.5 MSEK)
- Liquid assets on the balance sheet date amounted to 0.6 MSEK (1.2 MSEK)
- Equity as of December 31 amounted to 3.3 MSEK (41.1 MSEK)
The period January- December 2024
The group in total
- Net sales 2.2 MSEK (8.5 MSEK)
- Other income 0.1 MSEK (0.5 MSEK)
- R&D expenses for the period amounted to 22.1 MSEK (24.9 MSEK)
- Profit after tax amounted to -47.8 MSEK (-35.8 MSEK)
- Earnings per share for the period amounted to -0.38 SEK (-0.36 SEK)
- Cash flow from operating activities amounted to -12.0 MSEK (-9.1 MSEK)
| Datum | 2025-02-28, kl 10:10 |
| Källa | Cision |
SAVR är investeringsplattformen som utmanar branschen och gör det både enklare och roligare att investera. Betala aldrig för mycket! Alla aktier och ETF:er från 1 kr, och få upp till 50 % rabatt på alla fonder. Automatiskt courtage och samma enkla prismodell på alla marknader.